Rett syndrome
Drug research and approvals for rett syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 14 studies of rett syndrome are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, FDA has 2 approved and 17 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 14
- Trials authorized in Canada: 7
- FDA orphan approvals: 2
- EU medicines: 1
- Auditory EEG and Behavioral Assessments in Individuals With Rett SyndromeNCT07569445 · Not reported · University of Rochester · starts Jul 31, 2025
- A Phase 3 Study of Fenfluramine Hydrochloride in Rett SyndromeNCT07503444 · Phase 3 · UCB BIOSCIENCES, Inc. · starts Jul 14, 2026
- Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal…NCT07493096 · Not reported · Healing Hope International · starts Mar 1, 2026
- Repurposing Mirtazapine in Rett SyndromeNCT07430046 · Phase 2 · University of Trieste · starts Jul 9, 2025
- Rett REVOLUTION Trial: An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Rett SyndromeNCT07150013 · Phase 1 · Unravel Biosciences, Inc. · starts Mar 15, 2026
- To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett SyndromeNCT06840496 · Phase 3 · Biomed Industries, Inc. · starts Sep 30, 2026
- Cognitive Function in Rett Syndrome During Trofinetide TreatmentNCT06705816 · Not reported · University of Minnesota · starts Dec 1, 2024
- ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of…NCT06430385 · Phase 1 / Phase 2 · Ionis Pharmaceuticals, Inc. · starts Oct 21, 2024
- Neurophysiologic Biomarkers in Rett SyndromeNCT05932589 · Not reported · Children's Hospital of Philadelphia · starts Oct 11, 2023
Approved 1
Phase 3 5
- DextromethorphanSigma opioid receptor agonist
- Blarcamesine
- CannabidiolCannabinoid CB1 receptor negative allosteric modulator
- RisperidoneSerotonin 2a (5-HT2a) receptor antagonist
- DonepezilAcetylcholinesterase inhibitor
Phase 2 9
- MecaserminInsulin-like growth factor I receptor agonist
- DesipramineNorepinephrine transporter inhibitor
- Glatiramer acetate
- LovastatinHMG-CoA reductase inhibitor
- KetamineGlutamate [NMDA] receptor negative allosteric modulator
- SarizotanSerotonin 1a (5-HT1a) receptor agonist
- VatiquinoneQuinone reductase 1 modulator
- TriheptanoinSupplement
- Tridecanoate
Phase 1 or earlier 2
- FingolimodSphingosine 1-phosphate receptor agonist
- EsketamineGlutamate [NMDA] receptor negative allosteric modulator
How its trials ended
87 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 14 whose ending is known, 29% met their primary endpoint, 14% missed it and 57% stopped early.
- Completed, result not reported4046%
- Ongoing2124%
- Status unknown1214%
- Met its primary endpoint45%
- Stopped: other or unclear33%
- Missed its primary endpoint22%
- Stopped: lack of efficacy22%
- Stopped: sponsor or business decision22%
- Stopped: funding11%
| Jan 30, 2026 | A phase 3 randomized, double-blind, placebo-controlled, parallel group, multicenter study with open-label extension to evaluate the efficacy and safety of…Fenfluramine (ZX008) | UCB | Pending |
| Jun 21, 2024 | Reveal pediatric study: an open-label, randomized, dose-escalation and dose-expansion study of the safety tolerability and efficacy of a single it…TSHA-102 / Prednisolone / Sirolimus / Methylprednisolone | Taysha Gene Therapies | Ongoing |
| Mar 25, 2022 | An open-label, randomized, dose-escalation and dose-expansion study of the safety and preliminary efficacy of a single intrathecal administration of TSHA-102,…TSHA-102 / Prednisolone | Taysha Gene Therapies | Ongoing |
| May 5, 2021 | A 40-week, open-label extension study of trofinetide for the treatment of girls and women with rett syndromeTrofinetide | ACADIA Pharmaceuticals | Pending |
| Apr 7, 2021 | A double-blind, randomized, placebo-controlled, safety and efficacy study of ANAVEX2-73 in patients with rett syndromeBlarcamesine | Anavex Canada Ltd. | Closed |
| Nov 12, 2020 | A randomized, double-blind,placebo-controlled, parallel-group study of trofinetide for the treatment of girls and women with rett syndromeTrofinetide | ACADIA Pharmaceuticals | Pending |
| Mar 25, 2020 | A randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of cannabidiol oral solution (GWP42003-p; cbd-os) in patients with…Cannabis (cannabidiol;GWP42003-P) | GW Research Limited | Pending |
| Dec 11, 2025 | Daybue StixTreatment of Rett syndrome in adults and pediatric patients 2 years of age and older | ACADIA Pharmaceuticals Inc. | Approved |
| Mar 10, 2023 | DaybueTreatment of Rett syndrome in adults and pediatric patients 2 years of age and older | ACADIA Pharmaceuticals Inc. | Approved |
| Sep 6, 2026 | Recombinant serotype 9 adeno-associated virus encoding a…Treatment of Rett syndrome | GeneTrek Therapeutics (Shanghai) Co., Ltd. | Designated |
| Jul 26, 2026 | (S)-1-(L-Leucyl-L-arginyl)-2-methylpyrrolidine-2-carboxamideTreatment of Rett syndrome | ENCUE, Inc. | Designated |
| Nov 25, 2024 | CBDA dominant extract of Cannabis sativa / Low (<0.3% w/w)…Treatment of Rett syndrome | Neurotech International Limited | Designated |
| May 24, 2024 | VorinostatTreatment of Rett syndrome | Unravel Biosciences, Inc. | Designated |
| Mar 11, 2024 | Self-complementary Adeno-Associated Virus 9 containing…Treatment of Rett syndrome | Genecombio Ltd. | Designated |
| Mar 29, 2023 | 1-O-octadecyl-2-arachidonoyl-sn-glycerol-3-phosphoethanolami…Treatment of Rett syndrome | Neurocores Inc. | Designated |
| Feb 27, 2023 | Recombinant serotype 9 adeno-associated virus (AAV)…Treatment of Rett syndrome | Neurogene Inc. | Designated |
| Feb 1, 2023 | KetamineTreatment of Rett Syndrome | PharmaTher Inc. | Designated |
| Apr 19, 2022 | Methyl…Treatment of Rett Syndrome | DepYmed, Inc. | Designated |
| Oct 7, 2020 | Recombinant serotype 9 adeno-associated virus encoding a…Treatment for Rett syndrome | Taysha Gene Therapies | Designated |
| Jun 22, 2017 | [(S)-1-(L-valyl)-N_((S)-1-phenyl-2-(pyridin-2-yl)ethyl)pyrro…Treatment of Rett Syndrome | Biohaven Pharmaceutical Holding Company, Ltd. | Designated |
| Nov 30, 2016 | CannabidivarinTreatment of Rett syndrome | Jazz Pharmaceuticals Research UK Limited | Designated |
| Nov 3, 2016 | 6'-(R)-Methyl-5-O-(5-amino-5,6-dideoxy-a-L-talofuranosyl)-…Treatment of Rett syndrome | Eloxx Pharmaceuticals, Ltd. | Designated |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Aug 20, 2026 | DaybuTrofinetide · orphan | Acadia Pharmaceuticals B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA